论文部分内容阅读
缓释型维拉帕米是近年来广泛应用于临床的一种降压药，它的作用时间长，不会产生二氢吡啶类药物常见的反射性心率增加反应，与血管紧张素转换酶抑制剂（ＡＣＥＩ）、α肾上腺素受体阻滞剂、利尿剂及二氢吡啶类钙通道阻滞剂均能合用。长期应用不会抑制心肌，而且能逆转左室肥厚；对肾功能不全的病人，它不会减少肾血流量，并且可减少尿蛋白渗出；对预防心肌梗死后的冠状动脉再狭窄也有益处。本文对缓释型维拉帕米的药物动力学以及在降压、保护靶器官、预防血管再狭窄中的作用作了介绍
Sustained-release verapamil is widely used in clinical practice in recent years, a kind of antihypertensive drugs, its role for a long time, will not produce dihydropyridines common reflex heart rate response, and angiotensin-converting enzyme inhibition ACEI, alpha adrenergic blockers, diuretics and dihydropyridine calcium channel blockers can be combined. Long-term use does not inhibit the myocardium, but also reverse left ventricular hypertrophy; renal insufficiency patients, it will not reduce renal blood flow, and reduce urinary protein exudation; to prevent coronary artery restenosis after myocardial infarction is also beneficial. This article describes the pharmacokinetics of sustained-release verapamil and its role in blood pressure reduction, target organ protection, and prevention of vascular restenosis